Page 1808 - Williams Hematology ( PDFDrive )

1782 Part XI: Malignant Lymphoid Diseases Chapter 108: Immunoglobulin Light-Chain Amyloidosis 1783

62. Dinner S, Witteles W, Witteles R, et al: The prognostic value of diagnosing concur- 70. Gertz MA, Lacy MQ, Dispenzieri A, et al: Autologous stem cell transplant for immuno-
rent multiple myeloma in immunoglobulin light chain amyloidosis. Br J Haematol globulin light chain amyloidosis: A status report. Leuk Lymphoma 51(12):2181–2187,
161(3):367–372, 2013. 2010.
63. Kumar SK, Dispenzieri A, Lacy MQ, et al: Changes in serum-free light chain rather 71. Dispenzieri A, Dingli D, Kumar SK, et al: Discordance between serum cardiac
than intact monoclonal immunoglobulin levels predicts outcome following therapy in biomarker and immunoglobulin-free light-chain response in patients with immuno-
primary amyloidosis. Am J Hematol 86(3):251–255, 2011. globulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hema-
64. Gatt ME, Palladini G: Light chain amyloidosis 2012: A new era. Br J Haematol tol 85(10):757–759, 2010.
160(5):582–598, 2013. 72. Dispenzieri A, Buadi F, Laumann K, et al: Activity of pomalidomide in patients with
65. Chari A, Barley K, Jagannath S, Osman K: Safety and efficacy of triplet regimens in immunoglobulin light-chain amyloidosis. Blood 119(23):5397–5404, 2012.
newly diagnosed light chain amyloidosis. Clin Lymphoma Myeloma Leuk 13(1):55–61, 73. Dubrey SW, Reece DE, Sanchorawala V, et al: Bortezomib in a phase 1 trial for patients
2013. with relapsed AL amyloidosis: Cardiac responses and overall effects. QJM 104(11):
66. Palladini G, Milani P, Foli A, et al: Oral melphalan and dexamethasone grants extended 957–970, 2011.
survival with minimal toxicity in AL amyloidosis: Long-term results of a risk-adapted 74. Sher T, Hayman SR, Gertz MA: Treatment of primary systemic amyloidosis (AL): Role
approach. Haematologica 99(4):743–750, 2014. of intensive and standard therapy. Clin Adv Hematol Oncol 10(10):644–651, 2012.
67. Dispenzieri A, Seenithamby K, Lacy MQ, et al: Patients with immunoglobulin light 75. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al: Cyclophosphamide-bortezomib-
chain amyloidosis undergoing autologous stem cell transplantation have superior out- dexamethasone (CyBorD) produces rapid and complete hematologic response in
comes compared with patients with multiple myeloma: A retrospective review from a patients with AL amyloidosis. Blood 119(19):4391–4394, 2012.
tertiary referral center. Bone Marrow Transplant 48(10):1302–1307, 2013. 76. Yamasaki S, Muta T, Higo T, et al: Ventricular fibrillation after bortezomib therapy in a
68. Gertz MA, Dispenzieri A: Immunoglobulin light-chain amyloidosis: Growing rec- patient with systemic amyloidosis. Hematol Rep 5(3):e12, 2013.
ognition, new approaches to therapy, active clinical trials. Oncology (Williston Park) 77. Landau H, Hassoun H, Rosenzweig MA, et al: Bortezomib and dexamethasone consoli-
26(2):152–161, 2012. dation following risk-adapted melphalan and stem cell transplantation for patients with
69. Schonland SO, Dreger P, de Witte T, Hegenbart U: Current status of hematopoietic newly diagnosed light-chain amyloidosis. Leukemia 27(4):823–828, 2013.
cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone
Marrow Transplant 47(7):895–905, 2012.

Kaushansky_chapter 108_p1773-1784.indd 1783 9/18/15 9:53 AM